COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 9 of 94 for:    ASPIRIN AND thromboxane

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients (RITE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02008942
Recruitment Status : Completed
First Posted : December 11, 2013
Results First Posted : September 4, 2015
Last Update Posted : March 10, 2016
Information provided by (Responsible Party):
PLx Pharma

Brief Summary:
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as enteric coated aspirin, when administered to patients with diabetes

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: PL2200 Aspirin Capsules Drug: Enteric-coated aspirin caplets Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)
Study Start Date : January 2014
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Aspirin

Arm Intervention/treatment
Experimental: PL2200 Aspirin Capsules
PL2200 Aspirin Capsules
Drug: PL2200 Aspirin Capsules
325 mg aspirin; once per day for 10 days

Active Comparator: Enteric-coated aspirin caplets
Enteric-coated aspirin caplets
Drug: Enteric-coated aspirin caplets
325 mg aspirin; once per day for 10 days

Primary Outcome Measures :
  1. Time to 99% Inhibition of Serum Thromboxane [ Time Frame: 11 days ]
    Serial measurements of aspirin anti-platelet activity will be collected over 11 days, and compared between groups, to allow a determination of pharmacodynamic (anti-platelet) bioequivalence between study drugs. Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non-Insulin-Dependent Diabetes Mellitus
  • Adults 21 to 79 years, inclusive
  • Body mass index between 30 and 40 kg/m2, inclusive

Exclusion Criteria:

  • Currently prescribed aspirin or anti-coagulants
  • Contraindications to aspirin
  • Significant disease history or active disease other than Non-Insulin-Dependent Diabetes Mellitus
  • Patient requires insulin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02008942

Layout table for location information
United States, Florida
Miami Research Associates
Miami, Florida, United States, 33143
United States, Kansas
PRA Clinical Pharmacology Center
Lenexa, Kansas, United States, 66219
United States, Ohio
Medpace Clinical Pharmacology
Cincinnati, Ohio, United States, 45227
Sponsors and Collaborators
PLx Pharma
Layout table for additonal information
Responsible Party: PLx Pharma Identifier: NCT02008942    
Other Study ID Numbers: PL-ASA-006
First Posted: December 11, 2013    Key Record Dates
Results First Posted: September 4, 2015
Last Update Posted: March 10, 2016
Last Verified: February 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors